This study explores the role of stigma in cannabis use disclosure within the US healthcare system. Despite increasing societal acceptance and legislative changes, cannabis remains federally illegal in the USA, leading to reluctance among patients to disclose their cannabis use history. The study used a descriptive exploratory design with an anonymous, online national survey of adults aged 21 and older who had used cannabis and accessed healthcare within the last five years. The survey measured demographic characteristics, cannabis use patterns, and disclosure patterns, while stigma was assessed using the Stigma Use Stigma Mechanism Scale (SU-SMS) and Substance Abuse Self-Stigma Scale (SASSS). Key findings include: - Most participants (57.1%) initiated conversations about cannabis with their healthcare providers, but healthcare providers initiated only 15.1% of these discussions. - Anticipated stigma (95% CI 1.045–1.164) and total stigma (95% CI 1.001–1.039) were statistically significantly associated with nondisclosure. - Annual household income, chronicity of cannabis use, frequency of cannabis use, and known amount of CBD in consumed products were statistically significantly associated with the frequency of cannabis use disclosure. The study concludes that patients who use cannabis experience stigmatization in healthcare settings, which may limit their disclosure of cannabis use history. Future research should explore anticipated stigma more deeply, and healthcare providers should be better educated to lead conversations about cannabis while maintaining an unbiased perspective.This study explores the role of stigma in cannabis use disclosure within the US healthcare system. Despite increasing societal acceptance and legislative changes, cannabis remains federally illegal in the USA, leading to reluctance among patients to disclose their cannabis use history. The study used a descriptive exploratory design with an anonymous, online national survey of adults aged 21 and older who had used cannabis and accessed healthcare within the last five years. The survey measured demographic characteristics, cannabis use patterns, and disclosure patterns, while stigma was assessed using the Stigma Use Stigma Mechanism Scale (SU-SMS) and Substance Abuse Self-Stigma Scale (SASSS). Key findings include: - Most participants (57.1%) initiated conversations about cannabis with their healthcare providers, but healthcare providers initiated only 15.1% of these discussions. - Anticipated stigma (95% CI 1.045–1.164) and total stigma (95% CI 1.001–1.039) were statistically significantly associated with nondisclosure. - Annual household income, chronicity of cannabis use, frequency of cannabis use, and known amount of CBD in consumed products were statistically significantly associated with the frequency of cannabis use disclosure. The study concludes that patients who use cannabis experience stigmatization in healthcare settings, which may limit their disclosure of cannabis use history. Future research should explore anticipated stigma more deeply, and healthcare providers should be better educated to lead conversations about cannabis while maintaining an unbiased perspective.